The 61st American Society of Hematology (ASH) Annual Meeting (December 07–10, Orlando, USA) provided an excellent opportunity for hematology professionals to learn about and engage with the HARMONY Alliance. At our breakfast meeting, we shared exciting updates on the progress of HARMONY’s research projects and our poster presentation showcased the meaningful evidence being generated by HARMONY in multiple myeloma (MM).
The ELN-HARMONY breakfast meeting
Our breakfast meeting was held in collaboration with our valued Partner– ELN Foundation (European LeukemiaNet). During the meeting, HARMONY Project Leads shared status updates and preliminary findings of the ongoing HARMONY Research Projects in 7 Hematologic Malignancies. The objectives of the HARMONY Alliance to acquire more data, initiate novel Research Projects and increase the number of scientific publications communicating research outcomes, were also discussed among the presenters and attendees.
The HARMONY poster presentation
Dr Mattia D’Agostino, leader of the HARMONY Research Project in Multiple Myeloma (MM), presented a scientific poster outlining their improvements of the current prognostic tool for MM. Using 5584 patient records from the HARMONY Big Data Platform, researchers identified new parameters to improve the tool – the Revised International Staging System – to stage the disease, predict prognosis and subsequently select the most appropriate treatment for patients with MM.
HARMONY Research Projects are developing in collaboration with the HARMONY Patient Cluster to ensure a patient-centered approach. Myeloma Patients Europe, one of Patient organizations of the HARMONY Patient Cluster, has helped to progress the research that was presented at ASH. Read their views on HARMONY’s improvements to the clinical tool on the Myeloma Patients Europe website.
HARMONY Ambassadors presenting at the ELN-HARMONY Breakfast meeting at ASH2010 were: Jesús María Hernández Rivas, IBSAL - Guillermo Sanz, Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana - Lars Bullinger, Charite - Mattia D’Agostino, University of Turin - Pierre Fenaux, GFM and hôpital St Louis Paris - Valeria Santini, University of Florence - Natacha Bolaños, Lymphoma Coalition - Anthony Moorman, Newcastle University - Maria Theresa Voso, Tor Vergata University-Rome - Pam Bacon, Celgene.
See what other meetings HARMONY is holding and attending by visiting our meetings page.
Become involved with HARMONY. Contact us to find out how you can participate in ongoing and future research initiatives.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
